» Articles » PMID: 12124460

The Vaccinia Virus N1L Protein is an Intracellular Homodimer That Promotes Virulence

Overview
Journal J Gen Virol
Specialty Microbiology
Date 2002 Jul 19
PMID 12124460
Citations 73
Authors
Affiliations
Soon will be listed here.
Abstract

The vaccinia virus (VV) N1L gene encodes a protein of 14 kDa that was identified previously in the concentrated supernatant of virus-infected cells. Here we show that the protein is present predominantly (>90%) within cells rather than in the culture supernatant and it exists as a non-glycosylated, non-covalent homodimer. The N1L protein present in the culture supernatant was uncleaved at the N terminus and was released from cells more slowly than the VV A41L gene product, a secreted glycoprotein that has a conventional signal peptide. Bioinformatic analyses predict that the N1L protein is largely alpha-helical and show that it is conserved in many VV strains, in other orthopoxviruses and in members of other chordopoxvirus genera. However, database searches found no non-poxvirus proteins with significant amino acid similarity to N1L. A deletion mutant lacking the N1L gene replicated normally in cell culture, but was attenuated in intranasal and intradermal murine models compared to wild-type and revertant controls. The conservation of the N1L protein and the attenuated phenotype of the deletion mutant indicate an important role in the virus life-cycle.

Citing Articles

Vaccinia Virus: Mechanisms Supporting Immune Evasion and Successful Long-Term Protective Immunity.

Hsu J, Kim S, Anandasabapathy N Viruses. 2024; 16(6).

PMID: 38932162 PMC: 11209207. DOI: 10.3390/v16060870.


Tumor Tropism of DNA Viruses for Oncolytic Virotherapy.

Enow J, Sheikh H, Rahman M Viruses. 2023; 15(11).

PMID: 38005938 PMC: 10675630. DOI: 10.3390/v15112262.


Suppression of innate immunity by the vaccinia virus protein N1 promotes skin microbiota expansion and increased immune infiltration following vaccination.

Shmeleva E, Syafiq D, Moldoveanu A, Ferguson B, Smith G J Gen Virol. 2023; 103(11).

PMID: 36748513 PMC: 7614846. DOI: 10.1099/jgv.0.001814.


The employment of vaccinia virus for colorectal cancer treatment: A review of preclinical and clinical studies.

Ling Q, Zheng B, Chen X, Ye S, Cheng Q Hum Vaccin Immunother. 2022; 18(6):2143698.

PMID: 36369829 PMC: 9746450. DOI: 10.1080/21645515.2022.2143698.


Deletion of immunomodulatory genes as a novel approach to oncolytic vaccinia virus development.

Ho T, Mealiea D, Okamoto L, Stojdl D, McCart J Mol Ther Oncolytics. 2021; 22:85-97.

PMID: 34514091 PMC: 8411212. DOI: 10.1016/j.omto.2021.05.007.